A second Rosalind life-sciences model, “gpt-rosalind-discovery,” appeared on the company’s API pricing page on October 10.

On October 10, OpenAI’s API pricing page listed a second life-sciences model, **gpt-rosalind-discovery**, beside **gpt-rosalind-research**. The company had not announced the new model or explained how it differs. Both are priced at $5 per million input tokens, $0.50 per million cached input tokens and $25 per million output tokens; OpenAI says cache-write pricing does not apply. The listing signals a growing Rosalind model family aimed at biology and drug-development work, putting OpenAI more directly in competition for research teams at pharmaceutical and biotech organizations. But access is restricted: approved organizations may use Rosalind for internal research through OpenAI’s trusted-access program, not customer-facing products or external commercial applications. The appearance follows OpenAI’s April introduction of Rosalind, a reasoning model for biology, drug discovery and translational medicine, and its June update combining GPT-5.5 capabilities with stronger medicinal-chemistry and genomics performance.